ETS2 and acute myeloid leukemia: As an important transcription factor with mitogenic and oncogenic activity, high expression of ETS2 predicted poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation [23], but also its down-regulation would inhibit the invasion and metastasis of renal cell carcinoma cells [24].